1. Home
  2. FUSB vs PMN Comparison

FUSB vs PMN Comparison

Compare FUSB & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

N/A

Current Price

$15.75

Market Cap

91.4M

Sector

Finance

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$9.37

Market Cap

84.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
PMN
Founded
1952
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
84.1M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
FUSB
PMN
Price
$15.75
$9.37
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $42.71
AVG Volume (30 Days)
6.3K
★ 38.0K
Earning Date
10-28-2026
11-11-2026
Dividend Yield
★ 1.70%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.77
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.15
$0.29
52 Week High
$16.99
$27.40

Technical Indicators

Market Signals
Indicator
FUSB
PMN
Relative Strength Index (RSI) 52.22 27.95
Support Level $15.75 $9.20
Resistance Level $16.92 $15.37
Average True Range (ATR) 0.21 1.00
MACD 0.00 -0.38
Stochastic Oscillator 84.37 4.66

Price Performance

Historical Comparison
FUSB
PMN

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: